Contineum Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are filed as part of this Annual Report:
(1)Financial Statements. The financial statements filed as part of this Annual Report are included in Part II, Item 8 of this Annual Report.
(2)Financial Statement Schedules. Financial statement schedules have been omitted in this Annual Report because they are not applicable, not required under the instructions, or the information requested is set forth in the financial statements or notes thereto.
(3)Exhibits. The following is a list of exhibits filed or furnished as part of this Annual Report on Form 10-K.
Exhibits
| Incorporated by Reference · Filed | |||||
|---|---|---|---|---|---|
| ExhibitNumber · Description · Form · File No. · Exhibit · Filing Date · Herewith | |||||
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-42001 | 3.1 | 04/09/2024 |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K | 001-42001 | 3.2 | 04/09/2024 |
| 4.1 | Form of Registrant’s Class A common stock certificate. | S-1/A | 333-278003 | 4.1 | 04/01/2024 |
| 4.2 | Description of the Registrant’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934. | 10-K | 001-42001 | 4.2 | 03/06/2025 |
| 4.3 | Amended and Restated Investors’ Rights Agreement, dated February 9, 2021, by and among the Registrant and the other parties thereto. | S-1 | 333-278003 | 4.2 | 03/15/2024 |
| 4.4^ | Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of September 1, 2020. | S-1 | 333-278003 | 4.3 | 03/15/2024 |
| 4.5 | Letter Agreement, dated as of July 9, 2021, by and among the Registrant, Baker Bros. Advisors LP. | S-1 | 333-278003 | 4.4 | 03/15/2024 |
| 4.6 | Amended and Restated Registration Rights Agreement dated as of July 9, 2021, by and between the Registrant, 667, L.P. and Baker Brothers Life Sciences, L.P. | S-1 | 333-278003 | 4.5 | 03/15/2024 |
| 10.1+ | Form of Indemnity Agreement between the Registrant and each of its directors and executive officers. | S-1/A | 333-278003 | 10.1 | 04/01/2024 |
| 10.2+ | Contineum Therapeutics, Inc. 2012 Equity Incentive Plan, as amended, and forms of agreements thereunder. | S-1 | 333-278003 | 10.2 | 03/15/2024 |
| 10.3+ | Contineum Therapeutics, Inc. 2024 Equity Incentive Plan and forms of agreements thereunder. | S-1/A | 333-278003 | 10.3 | 04/01/2024 |
| 10.4+ | Contineum Therapeutics, Inc. 2024 Employee Stock Purchase Plan. | S-1/A | 333-278003 | 10.4 | 04/01/2024 |
| 10.5+ | Offer Letter, dated as of August 14, 2018, by and between the Registrant and Carmine Stengone. | S-1/A | 333-278003 | 10.5 | 04/01/2024 |
| 10.6+ | Offer Letter, dated as of March 9, 2018, as amended by Amendment to Original Offer Letter, dated as of December 16, 2021, each by and between the Registrant and Daniel Lorrain, Ph.D. | S-1/A | 333-278003 | 10.6 | 04/01/2024 | |
| 10.7+ | Offer Letter, dated as of August 20, 2020, by and between the Registrant and Peter Slover. | S-1/A | 333-278003 | 10.7 | 04/01/2024 | |
| 10.8+ | Offer Letter, dated May 28, 2024, by and between the Registrant and John Healy. | 10-Q | 001-42001 | 10.2 | 08/14/2024 | |
| 10.9+ | Contineum Therapeutics, Inc. Executive Severance Plan. | 8-K | 001-42001 | 10.1 | 05/31/2024 | |
| 10.10+ | Form of Registrant’s Mutual Arbitration Agreement. | 8-K | 001-42001 | 10.2 | 05/31/2024 | |
| 10.11^ | Lease Agreement, dated October 25, 2023, by and between ARE-3535/3566 General Atomics Court, LLC and the Registrant. | S-1 | 333-278003 | 10.13 | 03/15/2024 | |
| 10.12 † | License Agreement, dated February 3, 2023, by and between the Registrant and Janssen Pharmaceutica NV. | S-1 | 333-278003 | 10.16 | 03/15/2024 | |
| 10.13+^ | Offer Letter, dated as of April 3, 2025, by and between the Registrant and Tim Watkins. | 10-Q | 001-42001 | 10.1 | 08/05/2025 | |
| 10.14+ | Amendment to Offer Letter, dated as of April 18, 2025, by and between the Registrant and Tim Watkins. | 10-Q | 001-42001 | 10.2 | 08/05/2025 | |
| 10.15 | Sales Agreement, dated May 14, 2025, by and between Contineum Therapeutics, Inc. and Leerink Partners. | S-3 | 333-287275 | 1.2 | 05/14/2025 | |
| 10.16 | 2026 Employment Inducement Equity Incentive Plan and forms of agreements thereunder. | X | ||||
| 10.17+ | Amended Contineum Therapeutics, Inc. Non-Employee Director Compensation Program. | X | ||||
| 19.1^ | Contineum Therapeutics, Inc. Insider Trading Policy. | 10-K | 001-42001 | 19.1 | 03/06/2025 | |
| 21.1 | List of Subsidiaries. | 10-K | 001-42001 | 21.1 | 03/06/2025 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1* · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
|---|---|---|---|---|---|---|
| 32.2* · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 97.1 | Contineum Therapeutics, Inc. Policy for the Recovery of Erroneously Awarded Compensation | 10-K | 001-42001 | 97.1 | 03/06/2025 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | X | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | X | ||||
+Indicates management contract or compensatory plan.
†Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions are both not material and are the type of information that the Registrant treats as private or confidential.
^Pursuant to Item 601(a)(5) of Regulation S-K, certain exhibits and schedules have been omitted. The Registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request.
*The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates them by reference.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.